Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

@article{Byrd2006SelectHG,
  title={Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.},
  author={John C. Byrd and John G Gribben and Bercedis L. Peterson and Michael R Grever and Gerard Lozanski and David E. Lucas and Ben Lampson and Richard A Larson and Michael A. Caligiuri and Nyla A. Heerema},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 3},
  pages={437-43}
}
PURPOSE Several new prognostic factors predicting rapid disease progression in chronic lymphocytic leukemia (CLL) have been identified, including unmutated Ig V(H) mutational status, del(11)(q23), del(17)(p13.1), and p53 mutations. To date, the impact of these same prognostic factors have not been examined relative to treatment outcome with chemoimmunotherapy. METHODS We examined the impact of these new prognostic factors on predicting treatment outcome in symptomatic, untreated CLL patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 107 extracted citations

Chronic lymphocytic leukemia: diagnosis and treatment.

Mayo Clinic proceedings • 2006
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…